Efficacy and safety of PDE5 inhibitors in middle-aged and old patients with and without hypogonadism.

Chunlin WangHui ZhangFu WangJun GuoJianlin YuanGuangdong HouMing GaoZheng LiYan Zhangnull null

Published in: The aging male : the official journal of the International Society for the Study of the Aging Male (2023)

Eliminating or reducing reversible risk factors and controlling or slowing the development of irreversible factors is an important foundation for using PDE5i to treat ED in all patients, especially middle-aged and elderly ones.

Keyphrases

risk factors
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported outcomes